AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05311644 — intervention group
Intervention type: OTHER
Intervention: Telephone survey
Description: All participants are interviewed by telephone, and are asked to answer a survey.
Study NCT05648669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: 200 mg tablet
Study NCT05648669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elagolix placebo
Description: Elagolix-matched Placebo tablet
Study NCT05498480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days
Study NCT05498480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT05526118 — intervention group
Intervention type: DRUG
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: Patients who are ART-naive adults,18 years of age and older, diagnosed with HIV within 7 days of study entry who have a clinical (diagnosed Opportunistic Infection/AIDS-defining illness) or laboratory (CD4\<200) diagnosis of advanced HIV, who are clinically appropriate for Rapid ART initiation, and are initiated on bic/f/taf per DHHS guidelines at their initial clinic visit will be monitored for time to viral suppression, efficacy and CD4 cell recovery over the course of 48 weeks.
Study NCT05194839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIST4721
Description: RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
Study NCT05194839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05194839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT05832996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refresh Plus Preservative-free Lubricant Eye Drops
Description: Refresh Plus Preservative-free Lubricant Eye Drops at 4 degree Celsius
Study NCT05832996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Plus Preservative-free Lubricant Eye Drops
Description: Refresh Plus Preservative-free Lubricant Eye Drops at 4 degree Celsius
Study NCT05537051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM1021, PM8001
Description: Participants will be administered with PM1021 on Part A Day 1. Participants will be administered with PM1021 and PM8001 on Part B Day 1. PM1021 and PM8001 combination therapy administrated every 3 weeks from Part C Day 1 until disease progression, intolerable toxicity, until the patient withdraws/is withdrawn, or study completion.
Study NCT04966455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raisins
Description: Daily supplementation of 50 g of rainsins for 3 months
Study NCT06222645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICG fluorescence imaging technology
Description: Indocyanine green fluorescence imaging uses fluorescence intensity to assess blood perfusion of gastrointestinal anastomoses during gastrointestinal surgery
Study NCT06222645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICG fluorescence imaging technology
Description: Indocyanine green fluorescence imaging uses fluorescence intensity to assess blood perfusion of gastrointestinal anastomoses during gastrointestinal surgery
Study NCT06222645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imaging photoplethysmography
Description: Imaging photoplethysmography to assess blood perfusion at gastrointestinal anastomoses during gastrointestinal surgery
Study NCT06222645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging photoplethysmography
Description: Imaging photoplethysmography to assess blood perfusion at gastrointestinal anastomoses during gastrointestinal surgery
Study NCT05168904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fadraciclib
Description: Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
Study NCT05070260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous glenzocimab (ACT017) 1000 mg
Description: Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
Study NCT05070260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Description: Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
Study NCT05564819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The intervention group was given oral acetaminophen, once every 6 hours, for a total of 4 times.
Study NCT05564819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterilized water
Description: When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The control group was given sterilized water, once every 6 hours, for a total of 4 times.
Study NCT05632770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Collaborative Care
Description: Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
Study NCT05632770 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: American College of Surgeons (ACS) Required Screening and Referral (Usual Care)
Description: The study will contribute to usual care with the study 10-domain electronic health record (EHR) screen and the posttraumatic stress disorder (PTSD) evaluation. The study team may also collaborate with hospital providers on the referral process and/or inform a member of the patient's care team of distress patients are experiencing as identified by a DSM-5 PTSD Checklist (PCL) score of ≥ 30 or a DSM-IV PTSD Checklist (PCL) score of ≥ 35.
Study NCT06520163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Day 1\~Day 2: 75mg/m\^2
Study NCT06520163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Day 1\~Day 2: 200g/m\^2, q12h
Study NCT05140057 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Moviprep
Description: Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
Study NCT04997239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of quadrivalent influenza vaccine
Description: 15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
Study NCT04997239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One dose of quadrivalent influenza vaccine
Description: 15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
Study NCT05352360 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pilates Exercises
Description: Exercises with Kinesio Taping
Study NCT05352360 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Exercises with Kinesio Taping
Study NCT00106548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 4mg/kg iv / month
Study NCT00106548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv / month
Study NCT00106548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv / month
Study NCT06520163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: Day 6: 6mg
Study NCT06520163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
Study NCT00106548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg/week
Study NCT06520163 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: \[Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) \]± Rituximab (R)
Study NCT06520163 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hyper-CVAD
Description: \[Cyclophosphamide + Doxorubicin + Vincristine + Dexamethasone (DXM)\] ± Rituximab
Study NCT00106548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 10-25mg/week
Study NCT06520163 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ID-MTX + Ara-C
Description: \[High-Dose Methotrexate (MTX) + Cytarabine\] ± Rituximab
Study NCT06520163 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: DA-EPOCH
Description: \[Etoposide + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone\] ± Rituximab
Study NCT05841225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food-related inhibitory control training based on computer
Description: Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are high-calorie and low-calorie food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
Study NCT05841225 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-food-related inhibitory control training based on computer
Description: Inhibitory control training tasks are performed using E-Prime 3.0 software to present stimuli based on computer. The Go/no-go task is used as the training task, and the stimulus materials are non-food pictures. The training lasted for 5 days, once a day, and the total duration of each training is about 15 minutes.
Study NCT04642274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Correct the patient's low nutritional status before surgery.
Study NCT04642274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Blood Glucose
Description: Control the patient's blood glucose before surgery, fasting blood glucose level ≤ 8mmol/L or HbA1c ≤ 7%.
Study NCT04642274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Take 10% glucose water 6ml/kg 2 to 4 hours before operation (except for diabetes).
Study NCT04642274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking and Alcohol
Description: Quit smoking and alcohol before surgery
Study NCT04642274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Anemia
Description: Correct anemia before surgery
Study NCT04642274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Transfusion
Description: Use strict blood transfusion indications and blood protection strategy during surgery.
Study NCT04642274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GDFT
Description: Use goal-directed fluid therapy during surgery.
Study NCT04642274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remove the tracheal tube
Description: Remove the tracheal tube as soon as possible after surgery.
Study NCT04642274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating and Drinking
Description: Eat and drink as soon as possible after extubation after surgery.
Study NCT04642274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevent Thrombosis
Description: Actively prevent thrombosis after surgery.
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella vaccine
Description: Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
Study NCT06520163 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: GDP
Description: \[Gemcitabine (G) + Cisplatin (P) + Dexamethasone (DXM)\] ± Rituximab
Study NCT06520163 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: GDPE
Description: \[Gemcitabine + Cisplatin + Dexamethasone + Etoposide\] ± Rituximab
Study NCT06520163 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ICE
Description: \[Etoposide + Ifosfamide (IFO) + Carboplatin\] ± Rituximab
Study NCT06520163 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: DICE
Description: \[Dexamethasone + Ifosfamide + Ifosfamide + Etoposide\] ± Rituximab
Study NCT06520163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: From Day 6, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
Study NCT05091242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine injection 3 mcg/kg once
Study NCT05091242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride 0.9 % injection 0.2 mL/kg once
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever vaccine
Description: Yellow Fever vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever vaccine
Description: Yellow Fever vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants_9M_Dose A, Infants_9M_Control A, Infants_9M_Dose B, Infants_9M_Control B, Infants_9M_Dose C and Infants_9M_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants_6W_Dose A, Infants_6W_Control A, Infants_6W_Dose B, Infants_6W_Control B, Infants_6W_Dose C and Infants_6W_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
Study NCT06222944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib: 12mg PO, QD, D1-14, Q3W;
Study NCT06222944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450: 1200 mg, IV, D1, Q3W
Study NCT06222944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 125mg/m2 IV D1,8，Q3W
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentavalent vaccine
Description: Pentavalent vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentavalent vaccine
Description: Pentavalent vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine
Description: Pneumococcal vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine
Description: Pneumococcal vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated polio vaccine
Description: Inactivated polio vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine
Description: Inactivated polio vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants_6W_Dose A_2, Infants_6W_Dose B_2, Infants_6W_Dose C_2 and Infants_6W_Control_2 groups.
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNTS-GMMA Dose C
Description: -2 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1 and Day 57 to adults and children in the Adults_Dose C and Children_Dose C groups; -3 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants_9M_Dose C group, and at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants_6W_Dose C and Infants_6W_Dose C_2 groups.
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNTS-GMMA Dose B
Description: -2 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1 and Day 57 to children in the Children_Dose B group; -3 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants_9M_Dose B group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants_6W_Dose B and Infants_6W_Dose B_2 groups.
Study NCT06213506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNTS-GMMA Dose A
Description: 3 doses of iNTS-GMMA Dose A vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants_9M_Dose A group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants_6W_Dose A and Infants_6W_Dose A_2 groups.